Dossier
-
Angelini established a Joint Venture with Labopharm to commercialize Oleptro™ in the United States
In April 2010 Angelini has entered into an agreement with Labopharm Inc., an American pharmaceutical company, to establish a joint venture in the US for the commercialization of OLEPTRO™, a novel once-daily formulation of the antidepressant trazodone.continua
-
Scientific network: recent published results on bindarit
MCP-1/CCL2 is a chemokine that play a major role during inflammatory processes and it has been proposed as a new pharmacological target in several diseases.continua
Worldwide locations
|
|
|
|
Go to angelini site